Kardigan has filed plans with the US Securities and Exchange Commission to raise up to $100 million in an initial public offering as the company advances several late-stage cardiovascular disease therapies.

The Princeton, New Jersey-based biotech plans to list on the Nasdaq under the ticker symbol KARD. The IPO filing follows the company’s confidential submission made earlier in March 2026.

J.P. Morgan, Jefferies, Leerink Partners, and TD Cowen are acting as joint bookrunners for the offering.

Company Targets Major Cardiovascular Disease Markets

Kardigan is developing therapies focused on serious heart and vascular conditions through a pipeline of advanced clinical-stage drug candidates.

Its lead therapy candidate, danicamtiv, is currently in a Phase 2b/3 clinical study targeting genetic dilated cardiomyopathy linked to MYH7 and TTN gene variants. The oral therapy is designed to improve cardiac muscle performance in patients suffering from inherited heart failure conditions.

The company is also advancing ataciguat, an oral soluble guanylate cyclase activator currently being studied in a Phase 2b trial for calcific aortic valve stenosis progression. The therapy aims to address a major unmet need in slowing valve disease progression before surgical intervention becomes necessary.

A third candidate, tonlamarsen, is being developed as a once-monthly subcutaneous antisense oligonucleotide therapy designed for blood pressure management in post-hospitalization acute severe hypertension patients.

Proprietary Clinical Data Platform Adds Strategic Value

In addition to its therapeutic pipeline, Kardigan operates the Prolaio platform, a proprietary clinical data and analytics system designed to enhance real-world physiologic monitoring during clinical trials.

The platform integrates FDA-cleared algorithms with wearable sensor technology to continuously collect patient health data, potentially improving clinical trial efficiency and monitoring accuracy.

The combination of advanced cardiovascular therapies and integrated digital health infrastructure may position Kardigan differently from traditional single-asset biotechnology IPO candidates.

Biotech IPO Market Continues Showing Selective Strength

The filing arrives as biotechnology IPO activity remains selective, with institutional investors increasingly focusing on companies that demonstrate late-stage clinical progress and large addressable markets.

Cardiovascular disease remains one of the largest global healthcare segments, creating significant commercial potential for successful therapies targeting heart failure, hypertension, and structural heart diseases.

However, investors will likely continue monitoring clinical trial execution, regulatory pathways, and future financing needs given the capital-intensive nature of late-stage biotechnology development.

Kardigan was founded in 2023 and has rapidly assembled a pipeline centered on cardiovascular innovation, positioning itself among a growing group of biotech firms pursuing next-generation heart disease treatments through both therapeutic and digital health strategies.